References
- P. Pacher, A. Nivorozhkin, and C. Szabo, "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol", Pharmacol. Rev., Vol. 58, pp. 87-114, 2006. https://doi.org/10.1124/pr.58.1.6
- D. A. Parks and D. N. Granger, "Xanthine oxidase: biochemistry, distribution and physiology", Acta Physiol. Scand. Suppl., Vol. 548, pp. 87-99, 1986.
- M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Zeni, and P. Zardini, "Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy", Am. Heart. J., Vol. 143, pp. 1107-1111, 2002. https://doi.org/10.1067/mhj.2002.122122
- K. D, Pfeffer, T. P. Huecksteadt, and J. R. Hoidal, "Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation", J. Immunol., Vol. 153, pp. 1789-1797, 1994.
- H. M. Kramer and G. Curhan, "The association between gout and nephrolithiasis: the national health and nutrition examination survey III, 1988-1994", Am. J. Kidney Dis., Vol. 40, pp. 37-42, 2002. https://doi.org/10.1053/ajkd.2002.33911
- R. L. Wortmann, "Recent advances in the management of gout and hyperuricemia", Curr. Opin. Rheumatol., Vol. 17, pp. 319-324, 2005. https://doi.org/10.1097/01.bor.0000162060.25895.a5
- J. George and A. D. Struthers, "The role of urate and xanthine oxidase inhibitors in cardiovascular disease", Cardiovasc. Ther., Vol. 26, pp. 59-64, 2008.
- N. Dalbeth and L. Stamp, "Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events", Semin. Dial., Vol. 20, pp. 391-395, 2007. https://doi.org/10.1111/j.1525-139X.2007.00270.x
- T.-F. Tsai and T.-Y. Yeh, "Allopurinol in dermatology", Am. J. Clin. Dermatol., Vol. 11, pp. 225-232, 2010. https://doi.org/10.2165/11533190-000000000-00000
- B. L. Love, R. Barrons, A. Veverka, and K. M. Snider, "Urate-lowering therapy for gout: focus on febuxostat", Pharmacotherapy, Vol. 30, pp. 594-608, 2010. https://doi.org/10.1592/phco.30.6.594
- Tripos Sybyl, HQSAR manual.
- C. L. Waller, "A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds", J. Chem. Inf. Model., Vol. 44, pp. 758-765, 2004.
- W. Tong, D. R. Lowis, R. Perkins, Y. Chen, W. J. Welsh, D. W. Goddette, T. W. Heritage, and D. M. Sheehan, "Evaluation of quantitative structure- activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor", J. Chem. Inf. Model., Vol. 38, pp. 669-677, 1998.
- T. W Heritage and D. R. Lowis, "Molecular Hologram QSAR", In Rational Drug Design: Novel methodology and Practical Application, eds. A. L. Parrill, M. R. Reddy, Washington: America Chemical Society, Symposium Series, Vol. 719, pp. 212- 225, 1999.
- J. U. Song, S. P Choi, T. H. Kim, C.-K. Jung, J.- Y. Lee, S.-H. Jung, and G. T. Kim, "Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors", Bioorg. Med. Chem. Lett., Vol. 25, pp. 1254-1258, 2015. https://doi.org/10.1016/j.bmcl.2015.01.055
- D. A Winker and F. R. Burden, "Holographic QSAR of benzodiazepines", Mol. Inform., Vol. 17, pp. 224- 231, 1998.
- S. Wold, "Cross-validatory estimation of the number of components in factor and principal component model", Technometrics, Vol. 20, pp. 397-405, 1978. https://doi.org/10.1080/00401706.1978.10489693
Cited by
- Protein-Protein Interaction Analysis of Corticotropin - Releasing Hormone Receptor 1 with Corticotropin-Releasing Hormone and Sauvagine vol.11, pp.2, 2017, https://doi.org/10.13160/ricns.2018.11.2.101
- Hologram Based QSAR Analysis of Caspase-3 Inhibitors vol.11, pp.2, 2017, https://doi.org/10.13160/ricns.2018.11.2.93